425638-73-9

Basic information

• Product Name: 2-(2-(4-Methylpiperazin-1-yl)quinazolin-4-yl)acetaMide
• Synonyms: 2-(2-(4-Methylpiperazin-1-yl)quinazolin-4-yl)acetaMide
• CAS NO: 425638-73-9
• Molecular Formula: C15H19N5O
• Molecular Weight: 285.34426
• Mol File: 425638-73-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 557.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.257±0.06 g/cm3(Predicted)
• PKA: 15.22±0.40(Predicted)
• CAS DataBase Reference: 2-(2-(4-Methylpiperazin-1-yl)quinazolin-4-yl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-(4-Methylpiperazin-1-yl)quinazolin-4-yl)acetaMide(425638-73-9)
• EPA Substance Registry System: 2-(2-(4-Methylpiperazin-1-yl)quinazolin-4-yl)acetaMide(425638-73-9)

Safety Data

• Hazardous Substances Data: 425638-73-9(Hazardous Substances Data)

Usage

Chemical class

Quinazoline derivatives

Mechanism of action

Potent and selective inhibitor of cyclin-dependent kinases (CDKs) involved in cell cycle regulation

Potential use

Cancer therapy

Effects on cancer cells

Induces cell cycle arrest and apoptosis

Potential benefits

Overcoming drug resistance in cancer treatment

Upstream product

• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 
• 109-01-3 1-methyl-piperazine 
• 425638-74-0 2-(2-chloroquinazolin-4-yl)acetamide 
• 607-68-1 2,4-dichloroquinazoline 

Downstream Products

• 908351-31-5 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-1H-pyrrole-2,5-dione acetate 
• 425637-18-9 sotrastaurin 

Relevant articles and documents

INDOLYLMALEIMIDES AS SOFT PAN-PKC INHIBITORS

The present invention relates to new kinase inhibitors, more specifically soft PKC inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new soft PKC inhibitors compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including autoimmune and inflammatory diseases.

NOVEL THIENOPYRROLE COMPOUNDS

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treati

Indolylmaleimide derivatives

Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.